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Abstract: The rate of sudden cardiac death (SCD) for hemodialysis (HD) patients is significantly
higher than that observed in the general population and have the highest risk for arrhythmogenic
death. In this multi-center study, patients starting hemodialysis in each hospital were enrolled; they
underwent regular check-ups in an open-patient clinic. We examined serial electrocardiography
(ECG) data in patients undergoing HD and determined their associations with the occurrence of SCD.
Of 678 enrolled subjects who underwent serial ECG before and after hemodialysis, 291 died and 39
developed SCD. In all subjects, the QT peak-to-end (QTpe) interval at all leads and QRS duration
were shortened after hemodialysis. The SCD group showed a significant change in the QTpe interval
of the inferior, anterior, and lateral leads before and after hemodialysis compared with the survivor
group (p < 0.001). In the pre-hemodialysis ECG, SCD patients had significantly longer QTpe intervals
in all leads (p < 0.001) and a longer QRS duration (92.6 ± 14.0 vs. 100.6 ± 14.9 ms, p = 0.015) than
survivors. In conclusion, patients with a longer QTpe interval before hemodialysis and large changes
in ECG parameters after hemodialysis might be at a higher risk of SCD. Therefore, changes in the
ECG before and after hemodialysis could help to predict SCD.
Keywords: critical care; hemodialysis; death; sudden; cardiac; electrocardiography; kidney fail-
ure; arrhythmias
1. Introduction
According to the 2016 United States Renal Data System database, the most common
cause of mortality in patients with end-stage kidney disease (ESRD) undergoing dialysis
is cardiovascular disease (CVD), accounting for 41% of all deaths and 54% of deaths
with known causes in this population [1]. Among CVD deaths, sudden cardiac death
(SCD) is the largest cause of mortality in ESRD patients undergoing hemodialysis (HD) [2].
Although patients with ESRD undergoing HD constitute a relatively small population,
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SCD is significantly more common among them than in the general population, and ESRD
is the strongest risk factor for arrhythmogenic death [3]. Several studies have identified risk
factors for SCD in patients with ESRD undergoing HD, such as myocardial hypertrophy [4],
left ventricular diastolic dysfunction [5], myocardial fibrosis [6], and dialysis-induced
myocardial ischemia [7]. Furthermore, during HD, wide fluctuation of electrolytes such as
sodium, potassium, calcium, magnesium [8], and other ions may increase arrhythmia risk
in the long term as well as during HD [9,10].
Therefore, if patients at a high risk of SCD could be identified, preventive management
could be provided, including drug therapy and implantable cardioverter-defibrillator
placement. However, invasive methods such as coronary angiography and treadmill stress
tests are required to predict SCD risk in patients undergoing HD.
Among non-invasive methods, electrocardiography (ECG) reflects myocardial changes
such as the prolongation of QT interval, QTc interval, QTc dispersion, and QT peak-to-end
(QTpe) interval [11–15]. As mentioned in many previous reports, several risk factors of
SCD cause ventricular remodeling and myocardial fibrosis, leading to ventricular dysfunc-
tion and dys-synchronization [5–7], changes which are known to affect SCD risk [11–13].
Notwithstanding this accumulating evidence, studies in large populations are still lack-
ing, because of the low prevalence of ESRD [1,11]. In this study, we used a multi-center
database to examine (1) the serial changes in ECG findings in patients undergoing HD and
(2) how baseline ECG measurements and their changes are related to the occurrence of
cardiovascular diseases and SCD.
2. Methods
2.1. Study Design and Population
This multi-center, retrospective cohort study was approved by the Institutional Review
Board of the Ewha Womans University Mokdong hospital (2017-08-005) and conducted in
three tertiary referral hospitals (Yonsei University Medical Center, Ewha Womans Univer-
sity Medical Center, and National Health Insurance Service Ilsan Hospital) in South Korea.
This study enrolled patients who started HD in each hospital from November 1986 to
September 2015. In addition, the last follow up date was 26 November 2016. The exclusion
criteria were moderate to severe valvular heart diseases, congenital heart diseases, acute
myocardial infarction/unstable angina within the past 3 months, and any uncontrolled
metabolic disorders such as homocystinuria, glycogen storage diseases, and mitochondrial
disorders. The rate of SCD and ECG measurements before and after HD were analyzed.
2.2. Data Collection
Data from all subjects were obtained through review of the hospital’s medical records.
In case of missing medical records about the cause of death, telephone interviews were
conducted. Clinical data such as those of demographic characteristics, start date of HD,
presence of hypertension and diabetes mellitus, cause of death, and mortality were eval-
uated. Various laboratory data such as those of complete blood counts and blood urea
nitrogen, creatinine, and electrolyte levels after HD were collected. All subjects underwent
12-lead ECG and 2-dimensional transthoracic echocardiography (TTE) before starting HD,
which were repeated at regular intervals, together with laboratory tests, after starting HD.
Furthermore, cardiac function, in terms of ejection fraction (EF), left ventricle end-diastolic
dimension, left ventricle end-systolic dimension, and E/E’ ratio (E: mitral peak velocity of
early filling, E’: early diastolic mitral annular velocity), was measured by TTE before and
after HD.
2.3. Definitions
According to the 2006 American College of Cardiology/American Heart Associa-
tion/Heart Rhythm Society guidelines, SCD is defined as the sudden cessation of cardiac
activity regardless of whether resuscitation or spontaneous reversion occurs [16]. The
most commonly used definition of SCD is “death occurring within an hour of symptom
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onset with no clinical support for another cause,” [17] and we used the same definition in
our study.
Cause of death was defined as the event which directly led to death and was divided
into the following six mutually exclusive categories: (1) cardiovascular disease (including
SCD), (2) intracerebral hemorrhage, (3) major bleeding, (4) cancer, (5) sepsis/other infection,
or (6) other. Among them, major bleeding was defined as (1) fatal bleeding; (2) symp-
tomatic bleeding in a critical area or organ, such as intraspinal, intraocular, retroperitoneal,
intraarticular, pericardial, or intramuscular bleeding with compartment syndrome; and/or
(3) bleeding causing a decrease in the hemoglobin level of ≥2 g/dL or leading to the re-
quirement of transfusion. When the cause of death did not belong to the first five categories,
deaths were classified as deaths due to “other” causes.
HD duration was defined as the difference between the first HD date and the last
follow up date of HD patient.
The factors that may affect SCD are hypertension, diabetes mellitus, and atrial fibrilla-
tion (AF). Hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic
blood pressure ≥90 mmHg [18]. Diabetes mellitus was defined as fasting blood glucose
levels ≥126 mg/dL (fasting: no caloric intake for at least 8 h), hemoglobin A1c levels
≥6.5%, or a previous diagnosis [19]. AF was defined as a documented supraventricular
tachyarrhythmia with uncoordinated atrial activation and consequently, ineffective atrial
contraction [20].
2.4. ECG Analysis
ECG was performed for all participants using an ECG HP-Page-Writer TC 30 machine
(filter range 0.5–150 Hz, AC filter 60 Hz, 25 mm/s, 10 mm/mV). We measured the PR
interval, which extends from the beginning of the P wave until the beginning of the QRS
complex. QRS duration was defined as the time from the first downward deflection after
the P wave to the second downward deflection after the R wave. The QT interval was
measured from the onset of the QRS complex to end of the T wave that returned to the TP
baseline. Every QT interval was corrected for the patient heart rate using Bazett’s formula:
QTc = QT
√
RR (in milliseconds [ms]) [20]. The QTpe interval of each lead was measured
from the maximum amplitude of the T wave to the end of the T wave that meets the
isoelectric line [20]. QTc dispersion was defined as the difference between the maximum
and minimum QTc intervals in 12 leads [20]. The initial ECG was performed when the
patient was about to start HD, and the last ECG performed before cardiac death or the
end of follow-up in HD patients was considered as the final ECG. All ECG changes were
calculated as “ECG parameter before HD” minus “ECG parameter after HD,” and median
values were used for analysis. ECG measurements were performed manually with the
aid of software (Cardio Calipers, version 3.3, Iconico, Inc., New York, NY, USA) by two
researchers blinded to patient information.
2.5. Patient Follow-Up
Patients underwent regular check-ups at least twice a week in an open-patient clinic.
At each visit, the medical history of the patient was recorded, physical and laboratory
examinations were performed, including examinations for infection, drug history, and
electrolyte disturbance. We performed ECG at least once in 3 months.
2.6. Statistical Analysis
Continuous variables are reported as means ± standard deviations and were com-
pared using t-tests. Categorical variables are reported as numbers and percentages and
were compared between groups using χ2 tests and Fisher’s exact tests. ECG changes
before and after HD were compared between groups using a linear mixed model (LMM).
SCD risk is presented as a hazard ratio (HR), calculated using a Cox proportional hazards
model. The cut-off values of the QTpe intervals in each lead used in Cox analysis were
established using receiver operating characteristic (ROC) curves. For additional analyses,
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propensity score matching was used to reduce the effects of age and sex. All statistical
analyses were conducted using the SPSS software, version 25.0 (IBM, Armonk, NY, USA);
p-values <0.05 were considered significant. Propensity score matching was performed
using the R program, version 3.5.3 for Windows.
3. Results
3.1. Baseline Characteristics
During the study period (mean follow-up duration 63.6 ± 53 months), a total of 678
subjects who underwent serial ECG before and after HD were enrolled and followed-up,
among whom 291 died. Infection (n = 128, 44%) was the leading cause of death, followed
by cardiovascular diseases (n = 71, 24.4%), cancer (n = 33, 11.3%), intracerebral hemorrhage
(n = 26, 8.9%), major bleeding (n = 13, 4.5%), and others (n = 20, 6.9%). Among deaths from
cardiovascular diseases, 39 (54.9%) involved SCD (Figure 1A).
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Considering survivors and subjects with SCD, the prevalence of SCD was 9−13.6%
according to the HD period (Figure 1B). Table 1 shows the baseline characteristics of the
subjects, excluding those who died of causes other than SCD (survivors without SCD,
n = 387; those who died due to SCD, n = 39). No significant differences between these two
groups were found in sex, body surface area, body mass index, presence of hypertension,
mean HD duration, or mean sodium, potassium, or calcium levels measured after HD.
However, age (69.2 ± 12.5 vs. 59.8 ± 13.7 years, p < 0.001) and the proportion of subjects
with diabetes mellitus (78.9% vs. 53.6%, p = 0.003) were significantly higher in the SCD
group. Regarding TTE findings, the EF was significantly lower in the SCD group than in the
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survivor group both before and after HD (pre-HD TTE: 54.8± 12.4 vs. 59.4± 11.3, p = 0.037;
post-HD TTE: 46 ± 11.8 vs. 58.4 ± 11.6, p < 0.001), while the E/E′ ratio was significantly
higher in the SCD group than in the survivor group (pre-HD TTE: 19.4 ± 7.7 vs. 15.6 ± 6.6,
p = 0.011; post-HD TTE: 22.9 ± 9.4 vs. 17.2 ± 7.9, p = 0.018). Other parameters, such as left
ventricle end-diastolic dimension and left ventricle end-systolic dimension, showed no
significant differences.
Table 1. Baseline characteristics of the patients.
Variable Survivor (n = 387) SCD (n = 39) p-Value
Age (years) 59.8 ± 13.7 69.2 ± 12.5 <0.001
Male (n, %) 189 (48.8) 25 (64.1) 0.069
Body surface area (m2) 1.64 ± 0.19 1.66 ± 0.22 0.571
Body mass index (kg/m2) 23.0 ± 3.7 22.8 ± 3.9 0.78
Hypertension (n, %) 349 (90.2) 33 (84.6) 0.387
Diabetes mellitus (n, %) 206 (53.2) 30 (76.9) 0.003
Duration of HD (months) 64.5 ± 53.0 54.9 ± 52.8 0.294
Echocardiography before HD
Pre-HD LVEF (%) 59.4 ± 11.3 54.8 ± 12.4 0.037
Pre-HD LVEDD (mm) 51.9 ± 6.6 53.9 ± 10.1 0.367
Pre-HD LVESD (mm) 35.5 ± 7.3 38.1 ± 11.2 0.329
Pre-HD E/E′ 15.6 ± 6.6 19.4 ± 7.7 0.011
Echocardiography after HD
Post-HD- HD LVEF (%) 58.4 ± 11.6 46 ± 11.8 <0.001
Post-HD LVEDD (mm) 51.2 ± 6.0 52.7 ± 10.5 0.493
Post-HD LVESD (mm) 35.3 ± 7.1 39.9 ± 10.7 0.051
Post-HD E/E′ 17.2 ± 7.9 22.9 ± 9.4 0.018
Laboratory findings after HD
Hb (g/dL) 10.5 ± 1.4 9.3 ± 1.5 <0.001
Hct (%) 32.6 ± 7.8 28.2 ± 4.8 0.017
BUN (mg/dL) 54.8 ± 21.9 58.5 ± 30.7 0.611
Cr (mg/dL) 8.4 ± 3.2 6.8 ± 3.7 0.039
eGFR (EPI) 6.5 ± 5.6 10.0 ± 8.4 0.091
Sodium (mEq/L) 137 ± 9.8 137.6 ± 5.4 0.764
Potassium (mEq/L) 4.9 ± 0.8 4.8 ± 1.3 0.642
T.Calcium (mg/dL) 8.9 ± 1.0 8.6 ± 0.7 0.352
Values are expressed as n (%) or means (standard deviations) unless otherwise indicated; SCD, sudden cardiac
death; HD, hemodialysis; LV, left ventricle; EF, ejected fraction; LVEDD, left ventricle end-diastolic dimension;
LVESD, left ventricle end-systolic dimension; E/E′, E: mitral peak velocity of early filling, E′: early diastolic mitral
annular velocity; Hb, hemoglobin; Hct, hematocrit; BUN, blood urea nitrogen; Cr, creatinine; eGFR, estimated
glomerular filtration rate; T.Calcium, Total calcium.
3.2. ECG Findings in the SCD Group
Tables 2 and 3 show the analysis of ECG findings before and after HD. In the pre-HD
ECG analysis, SCD patients had a significantly longer QTpe interval at all leads (II, III,
aVF, and V1-6 leads, p < 0.001) and a longer QRS duration than survivors (100.6 ± 14.9 vs.
92.6 ± 14.0 ms, p = 0.015). The proportion of patients with AF was significantly higher in
the SCD group (11.1% vs. 1.9%, p = 0.028). Other variables including heart rate, PR interval,
QT interval, QTc interval, and dispersion of QT did not show significant differences
between the two groups. However, interestingly, in the post-HD ECG analysis, there
were no significant differences in any of the variables (QTpe intervals at all leads, QRS
duration, or proportion of patients with AF) that had shown differences in the pre-HD
ECG analysis. Only heart rate was significantly higher in the SCD group (89.8 ± 22.3 vs.
81.9 ± 15.6 beats/min, p = 0.037).
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Table 2. Baseline ECG findings before hemodialysis.
Variable Survivor (n = 387) SCD (n = 39) p-Value
Atrial fibrillation (n, %) 5 (1.3) 3 (7.7) 0.028
Heart rate (/min) 76.2 ± 14.6 80.6 ± 16.7 0.141
PR interval (ms) 168.9 ± 27.6 175.2 ± 37.9 0.377
QRS duration (ms) 92.6 ± 14.0 100.6 ± 14.9 0.015
QT interval (ms) 405.5 ± 47.9 395.6 ± 49.0 0.307
QTc interval (ms) 451.8 ± 28.8 456.2 ± 29.9 0.449
Dispersion of QT (ms) 55.5 ± 32.4 67.9 ± 22.7 0.052
QT Peak-end interval (ms)
II 113.4 ± 50.0 183.9 ± 67.4 <0.001
III 110.0 ± 69.2 174.8 ± 72.3 <0.001
aVF 108.4 ± 48.4 178.4 ± 70.8 <0.001
V1 112.0 ± 49.6 192.5 ± 70.5 <0.001
V2 123.9 ± 51.5 206.8 ± 67.7 <0.001
V3 126.3 ± 53.3 209.7 ± 75.9 <0.001
V4 122.2 ± 54.5 201.8 ± 71.8 <0.001
V5 121.1 ± 53.6 202.1 ± 76.7 <0.001
V6 118.5 ± 54.4 200.3 ± 80.8 <0.001
Values are expressed as n (%) or means (standard deviations) unless otherwise indicated; SCD, sudden cardiac
death; ECG, electrocardiography.
Table 3. Baseline ECG findings after hemodialysis.
Variable Survivor (n = 387) SCD (n = 39) p-Value
Atrial fibrillation (n, %) 12 (3.1) 3 (7.7) 0.138
Heart rate (/min) 81.9 ± 15.6 89.8 ± 22.3 0.037
PR interval (ms) 171.2 ± 31.8 151.0 ± 44.6 0.106
QRS duration (ms) 95.2 ± 26.1 105.6 ± 33.0 0.099
QT interval (ms) 409.0 ± 51.4 396.9 ± 62.7 0.279
QTc interval (ms) 459.6 ± 46.8 464.1 ± 47.3 0.601
Dispersion of QT (ms) 52.0 ± 21 66.6 ± 43.8 0.075
QT Peak-end interval (ms)
II 89.1 ± 37.0 83.3 ± 37.1 0.419
III 84.2 ± 52.5 81.5 ± 35.3 0.781
aVF 83.3 ± 20.3 78.4 ± 31.9 0.413
V1 88.3 ± 22.9 92.0 ± 22.0 0.407
V2 102.1 ± 50.5 90.4 ± 21.4 0.232
V3 102.0 ± 20.0 94.2 ± 24.8 0.096
V4 98.4 ± 26.8 93.7 ± 28.3 0.382
V5 93.5 ± 21.9 86.0 ± 22.2 0.079
V6 90.0 ± 20.5 91.3 ± 25.8 0.802
Values are expressed as n (%) or means (standard deviations) unless otherwise indicated; SCD, sudden cardiac
death; ECG, electrocardiography.
3.3. Changes in ECG Parameters before and after HD in the Two Groups
Table 4 and Figure 2 show the median change in each ECG parameter after HD in the
two groups. There were no significant differences the changes in QT interval, QTc interval,
or dispersion of QT between the two groups. However, the change in QTpe interval after
HD was significantly greater in the SCD group than in survivors. Furthermore, in the
LMM analysis, the SCD group showed a significantly larger change in the QTpe intervals
of the inferior, anterior, and lateral leads after HD than the survivor group (Figure 2,
Supplementary Figure S1; all leads, p < 0.001).
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Table 4. Changes in ECG parameters after HD (ECG before HD-ECG after HD).
Variable Survivor (n = 387) SCD (n = 39) p-Value
QT interval (ms) −6 (−36, 26) 38 (−25, 84) 0.963
QTc interval (ms) −8.5 (−32, 12) 1 (−13.5, 58) 0.937
Dispersion of QT (ms) 4.3 (−13.9, 27.8) 32 (1, 48) 0.02
QT Peak-end interval (ms)
II 8 (−9.4, −71.2) 112 (82, 128) <0.001
III 12 (−8, 69.4) 96 (66, 140) <0.001
aVF 12 (−8, 61.8) 132 (96, 142) <0.001
V1 8 (−12, 64.4) 140 (98.0−150) <0.001
V2 12 (−8, 63) 140 (94, 168) <0.001
V3 8.7 (−8, 70.2) 152 (114, 186) <0.001
V4 8 (−10, 64.7) 140 (80, 164) <0.001
V5 12 (−9.2, 96.6) 160 (142, 176) <0.001
V6 12 (−4.2, 66.2) 152 (90, 174) <0.001
Values are expressed as medians (interquartile range); ECG, electrocardiography; HD, hemodialysis; SCD, sudden
cardiac death.
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The change in QT peak-to-end (QTpe) interval before and after HD in the sudden cardiac death (SCD) group and the
change in QTpe interval before and after HD in the survivor group were statistically significant. The SCD group showed a
significantly larger change in the QTpe intervals of the inferior, anterior, and lateral leads after HD than the survivor group.
3.4. ECG Parameters as Predictors of SCD
ROC curve an lysis showed the ability of the pre-HD QTpe interval (at all leads) to
predict SCD (Supplementary Table S1). In particular, the area under the curve of the QTpe
interval at the V2 lead was 0.830 (95% confidence interval [CI], 0.741–0.919). The optimal
cut-off value of 148.1 ms for the QTpe interval at the V2 lead was determined using ROC
curve analysis. Indeed, in multivariable Cox regression analysis, a QTpe interval at the V2
lead >148.1 ms was significantly associated with SCD after adjusting factors including age,
sex, di bete mellitus, AF and EF before HD (HR: 33.793, CI: 4.446–256.845) (Table 5).
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Table 5. Cox analysis of the risk of sudden cardiac death predicted by ECG parameters.
Hazard Ratio 95% Confidence Interval p-Value
Age 1.051 1.005–1.100 0.030
Sex, male 1.846 0.623–5.470 0.269
Diabetes mellitus 3.276 0.719–14.936 0.125
Atrial fibrillation before hemodialysis 8.061 1.886–34.449 0.005
Ejection fraction in echocardiography before hemodialysis 0.975 0.934–1.019 0.259
QTpe interval at the V2 lead > 148.1 ms before hemodialysis 33.793 4.446–256.845 0.001
QTpe: QT peak-to-end.
3.5. Additional Analyses
Since there was a significant difference in age between survivors and SCD patients,
additional analyses were performed using propensity score matching to reduce the effects
of age and sex (Supplementary Tables S2–S4). After age- and sex-matching, SCD patients
showed a significantly longer pre-HD QTpe interval at all leads (II, III, aVF, and V1-6 leads,
p < 0.001) than survivors (Supplementary Table S3).
Moreover, in an additional analysis based on cardiovascular mortality including SCD,
acute coronary diseases, and heart failure, 378 survivors and 71 patients who died of CVD
were compared. Detailed results are described in the Supplementary Tables S5–S8. Similar
to the SCD analysis, the additional CVD analysis showed that a longer pre-HD QTpe
interval was an important predictor of CVD mortality. Moreover, the changes in some ECG
parameters after HD were also significantly greater in the CVD mortality group than in the
survivor group (QTpe intervals at the II-V6 leads, p < 0.001, Supplementary Figure S2). The
QTc interval was significantly prolonged after HD in the CVD mortality group compared
to that in the survivor group (466.9 ± 33.7 vs. 451.8 ± 28.8 ms, p = 0.001).
Lastly, to determine whether there was a difference according to the duration of the
HD, we studied additional analysis. Both patients who received HD less than 1 year and
those who received HD older than 1 year showed similar results to analysis which were
conducted with all patients (Supplementary Tables S9–S12).
4. Discussion
In this study, we found that SCD developed in 9−13.6% of HD patients, and these
patients showed a significantly longer QTpe interval and QRS duration at all leads before
HD initiation. Moreover, ECG changes after HD were significantly greater in the SCD
group than in the survivor group.
4.1. Clinical Implications of the QTpe Interval in This Study and Previous Studies
SCD in ESRD is a major cause of mortality, and previous studies have reported various
risk factors including age, poor nutrition, decreased heart function, and inflammation [2,21].
Among ECG parameters, increased QTpe interval is known to be associated with sudden
cardiac death [22]. Our study showed a significantly longer QTpe interval on the pre-
HD ECG in the SCD group, similar to this previous study. However, the QTpe interval
was shortened after HD in our study. The peak of the T wave represents the end of the
repolarization of epicardial cells, while its end represents the end of the repolarization of
endocardial cells. Therefore, the interval from the peak to the end of the T wave is closely
related to the global transmural dispersion of repolarization (TDR) in the ventricular
myocardium [23]. A prolonged QTpe interval may induce an extended vulnerable period
and given the right conditions, could increase the risk of ventricular arrhythmogenesis [24].
Moreover, various studies have reported that QTpe interval prolongation is correlated with
arrhythmic instability and can be an index of ventricular repolarization [24–27]. Thus, the
QTpe interval predicts ventricular tachycardia/ventricular fibrillation and death, as its
increase has been correlated with the risk of ventricular tachyarrhythmia and mortality [28].
Considered the aforementioned results, a longer QTpe interval could be considered a risk
factor for SCD.
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4.2. Comparison with Other Studies: An Explanatory Hypothesis
In our study, the QTpe interval after HD in both groups was close to normal [29], with
no differences between the two groups. Our hypothesis to explain these findings is as
follows. Chronic kidney disease frequently causes cardiac remodeling with hypertrophy,
capillary loss, and fibrosis [30]. Progression of myocardial fibrosis could lead to increased
dispersion of repolarization and an increased QTpe interval on ECG [31]. In other words,
patients with longer QTpe intervals are more likely to have undergone cardiac remodel-
ing. HD ameliorates the factors causing cardiac remodeling, including volume overload,
removes uremic toxins, and corrects electrolyte imbalance [30,32], and this might shorten
the QTpe interval. A recent study reported no differences in QTpe intervals between
the SCD and survivor groups among HD patients, similar to our results [33]. Another
possibility is that a greater change in TDR due to HD resulted in vulnerability to ventricular
arrhythmogenesis in a situation involving cardiac remodeling caused by chronic kidney
disease. HD patients are always exposed to rapid changes in blood pressure, volume, and
electrical conductance of the myocardium when receiving HD. A prolonged QTpe interval
before HD suggests a cardiac structural defect, and a defective structure may be more
strongly affected by rapid hemodynamic changes. Indeed, in our study, the SCD group
showed decreased EF and increased E/E’ on TTE both before and after HD.
4.3. Clinical Implications of the QTc Interval and QT Dispersion in This Study and
Previous Studies
Several studies have reported an increased QTc interval and increased QT dispersion
on ECG in various populations, including ESRD patients, as risk factors for SCD [12,13,34].
However, in our study, the QTc interval was not prolonged compared to its normal value
before or after HD [35]. QT dispersion, as in other studies, was >50 ms both before and after
HD; hence, it was higher than normal [14,15] but was not different between the SCD and
survivor groups. It may be conjectured that previous studies focused on cardiovascular
mortality rather than SCD, potentially explaining the difference with our results. In our
additional analysis of cardiovascular mortality, the pre-HD QTc interval and QT dispersion
were significantly different between the survivor and cardiovascular mortality groups
(Supplementary Table S7). Although various studies have reported that the QTc interval
and QT dispersion are associated with cardiovascular mortality in ESRD patients, a clear
association between QT dispersion and SCD in the ESRD population has not yet been
observed [11].
4.4. Limitations
Our study has several limitations. First, although we enrolled a large sample of
patients from three tertiary hospitals, our study population was entirely Asian. Therefore,
our findings may not be generalizable to other ethnicities. Second, our study design was
retrospective, and some patients’ mortality data were acquired via telephone interviews,
which might have led to some bias. However, most ESRD patients with HD underwent
regular check-ups at the open-patient clinic, suggesting that any bias would likely be small.
Furthermore, we performed additional analyses to reduce the effects of age and sex using
propensity score matching. However, some data including vascular access and all serial
ECG for each patient was not collected. Further, since enrolled patients were extracted
from the registry, some patients might not be included. Therefore, it is necessary to pay
attention to the interpretation of the results. Third, we could not confirm our hypothesis
about myocardial fibrosis in ESRD patients with HD presented in the Discussion. Fibrosis
of the myocardium could be confirmed using biomarkers (tumor necrosis factor alpha,
matrix metalloproteinase-2, and cytokines) or through magnetic resonance imaging. Lastly
we only compared the initial ECG before start HD with the last ECG performed before
cardiac death or the end of follow-up in HD patients. Therefore, we could not find ECG
parameters change over time the longer patients stayed on HD in this study. Therefore,
further studies are needed to confirm and improve on our results.
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5. Conclusions
Our results demonstrate that ECG parameters before and after HD may help in
predicting SCD in ESRD patients. The QTpe interval at all leads and QRS duration were
shortened after HD. Patients with a longer QTpe interval before HD and large ECG changes
after HD might have a relatively higher SCD risk.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/jcm10091933/s1, Figure S1: Comparison of ECG changes before and after HD in survivors
and SCD patients using a linear mixing model, Figure S2: Comparison of ECG changes before
and after HD in survivors and CVD death patients using a linear mixing model, Table S1: ROC
analysis of the pre-HD QT peak-end interval at all leads as predictors of SCD, Table S2: Baseline
characteristics of survivors and SCD patients after propensity score matching for age and sex,
Table S3: Pre-hemodialysis ECG findings after propensity score matching for age and sex, Table S4:
Post-hemodialysis ECG findings after propensity score matching for age and sex, Table S5: Baseline
characteristics of survivors and cardiovascular disease patients, Table S6: Pre-hemodialysis ECG
findings of survivors and cardiovascular disease patients, Table S7: Post-hemodialysis ECG findings
of survivors and cardiovascular disease patients, Table S8: Changes in ECG parameters after HD
(ECG before HD-ECG after HD), Table S9: Baseline characteristics of the patients who older than 12
months after HD, Table S10: Pre-hemodialysis ECG findings of the patients who older than 12 months
after HD, Table S11: Post-hemodialysis ECG findings of the patients who older than 12 months after
HD, Table S12: Changes in ECG parameters after HD (ECG before HD-ECG after HD) in patients
who older than 12 months after HD.
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